Market2026 · 06
EU Drug Report's Unseen Impact on UK Medical Cannabis Supply Chains
Medicexum delves into the recently published European Drug Report 2026, exposing how its findings, despite focusing on illicit markets, project significant, yet underestimated, challenges and opportunities for UK legal medical cannabis operators, particularly concerning supply chain resilience and regulatory alignment. We examine the ripple effects for sponsors, Responsible Persons, and ultimately, patients.